Figure 1.
Flowchart of the allocation of 177 individuals with paracoccidiodomycosis according to treatment and time-point of outcome analysis.
Table 1.
Distribution of 177 individuals with paracoccidiodomycosis subjected to initial and complementary treatment according to epidemiological, clinical, and serologic features.
Figure 2.
Efficacy (A) and effectiveness (B) of initial treatment in 177 individuals with paracoccidiodomycosis according to the therapeutic regimen used, and efficacy (C) and effectiveness (D) of complementary treatment in 138 individuals with paracoccidiodomycosis according to the therapeutic regimen used.
Figure 3.
Kaplan-Meier curves assessing the time to clinical and serologic cure in individuals with paracoccidiodomycosis according to the antifungal agent used and the clinical form of disease.
A–C: assessment of clinical cure in 177 individuals - (A) acute/subacute form; (B) chronic form; (C) acute/subacute and chronic forms. D–F: assessment of serologic cure in 138 individuals - (D) acute/subacute form; (E) chronic form; (F) acute/subacute and chronic forms.
Table 2.
Kaplan-Meier analysis comparing the time in days to clinical and serologic cure in 177 and 138 individuals with paracoccidiodomycosis, respectively, according to the antifungal agent used and the clinical form of disease.
Table 3.
Kaplan-Meier analysis comparing the time in days to return to the normal values of erythrocyte sedimentation rate (ESR) and markers of active inflammation in 177 individuals with paracoccidiodomycosis according to the antifungal agent used and the clinical form of disease.
Table 4.
Multivariate analysis performed to identify predictors of the time to serologic cure in 138 individuals with paracoccidoidomycosis.
Table 5.
Blood chemistry alterations secondary to the use of antifungal agents in 177 individuals with paracoccidiodomycosis.
Table 6.
Sensitivity of the erythrocyte sedimentation rate and markers of active inflammation before the onset of antifungal treatment in 177 individuals with paracoccidiodomycosis.
Table 7.
Pairwise comparison of the sensitivity of the erythrocyte sedimentation rate and markers of active inflammation and assessment of the concordance degree in 169 individuals with paracoccidiodomycosis.